Jason Salganick, MD
Medical Oncology · Phoenix, AZNPI 1124125174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,246,967 of the $1,614,349 with a category attached, or 77.2%. 60 manufacturers reported payments, led by Incyte Corporation at 32.0% of the total. Among medical oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,821 payments — averaging $572.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$517K
- Taiho Oncology, Inc.$301K
- E.r. Squibb & Sons, L.L.C.$146K
- Sobi, Inc$143K
- AstraZeneca$108K
- GSK$69K
- plus $330K from 54 others
Across 2 payments — averaging $12,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$24K
What the payments were for
- Consulting fees$125,4678%
- Speaking & faculty fees$1,246,96777%
- Grants$2500%
- Travel & lodging$193,09412%
- Food & beverage$47,6873%
- Education$4850%
- Other$3990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,614,349 in reported general payments places this provider in the 95th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $466,900 |
| OjjaaraMomelotinib Dihydrochloride | 15 | $419,646 |
| Lenalidomide | 26 | $305,238 |
| VenclextaVenetoclax | 15 | $202,443 |
| InqoviDecitabine/Cedazuridine | 22 | $193,828 |
| EliquisApixaban | 41 | $28,614 |
| XareltoRivaroxaban | 26 | $19,149 |
| Hydroxyurea | 61 | $1,575 |
| Acyclovir | 118 | $966 |
| Ondansetron OdtOndansetron | 55 | $937 |
| Letrozole | 37 | $872 |
| Dexamethasone | 41 | $638 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 51 | $416 |
| Levofloxacin | 15 | $275 |
| Anastrozole | 16 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $46,787 | $466,90023 claims |
| GSKOjjaara | $68,988 | $419,64615 claims |
| AbbVieVenclexta | $3,118 | $202,44315 claims |
| Taiho Oncology, Inc.Inqovi | $300,621 | $193,82822 claims |
| PfizerEliquis | $3,328 | $28,61441 claims |
| Johnson & JohnsonXarelto | $2,572 | $19,14926 claims |
| Lilly USA, LLCOlanzapine | $451 | $18016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Phoenix
- Waqas ArslanPhoenix$39K
- Amber FlahertyPhoenix$38K
- Amir AzadiPhoenix$25K
- Mital PatelPhoenix$13K
- Haider ZafarPhoenix$7K
- Harshita ParipatiPhoenix$7K
- Debra WongPhoenix$6K
- Angela SaverimuthuPhoenix$1K
- Albert WendtPhoenix$474
- Vamsee TorriPhoenix$368
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.